PRINCETON, N.J. — Dr. Reddy’s Laboratories Ltd. has introduced sugammadex injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials, a generic equivalent of Merck's Bridion, in the U.S.
The rollout expands Dr. Reddy's hospital portfolio and reinforces its commitment to improving patient access to affordable, high-quality medicines.
Sugammadex injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. The launch is on the first day of generic availability in the U.S., underscoring Dr. Reddy's commitment to execution excellence and supply reliability.
Sugammadex injection (100mg/ml) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 and older undergoing surgery.
Bridion had U.S. sales of approximately $1.6 billion for the year ended in May, according to IQVIA.
